drugset / Trial / NCT02546999

Summary

In Norway, about 60% of all children with cerebral palsy (CP) are being treated with botulinum toxin A (BoNT-A) at 6 years of age, mainly in the legs. Despite this widespread use of the drug, the evidence for a positive effect on walking is insufficient. Moreover, large variation in effect is seen by clinicians. The main objective of the present study is to investigate whether injections with BoNT-A in the calf muscles make walking easier in children with spastic CP within 6 months, reflected by reduced energy cost during walking.

Timeline

Start
2015-09
Primary completion
2021-10-15
Completion
2021-10-15

Outcome

Missed primary endpoint

paper The mean change in energy cost did not differ significantly between groups at the primary time point P2 PMID 39058740 ↗

paper One treatment with BoNT-A was not superior to placebo in making walking easier in children with CP PMID 39058740 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject botulinum neurotoxin A Unknown 2 iu/kg Intramuscular
Subject botulinum neurotoxin A Unknown 50 iu Intramuscular
Subject botulinum neurotoxin A Unknown 60 iu Intramuscular
Subject botulinum neurotoxin A Unknown 420 iu Intramuscular

Indications